Metraipolis › archive › dc_adbc16d6bbc6
HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives — Europe PMC PMID:41550808
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41550808
- DOI
- 10.1039/d5ra09034b
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T18:51:17.729Z
- SHA-256 of the archived text
be940c21e3fa21eee8608597adc88e5079b037845534e9e430eeda32c7194118- Stable URL of this page
https://metraipolis.com/documento/dc_adbc16d6bbc6
How to cite
HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives — Europe PMC PMID:41550808 — Europe PMC (en), https://europepmc.org/article/MED/41550808 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_adbc16d6bbc6 (Metraipolis archive dc_adbc16d6bbc6, sha256 be940c21e3fa21eee8608597adc88e5079b037845534e9e430eeda32c7194118)
BibTeX
@misc{dcadbc16d6bbc6,
title = {HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives — Europe PMC PMID:41550808},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41550808},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_adbc16d6bbc6; sha256 be940c21e3fa21eee8608597adc88e5079b037845534e9e430eeda32c7194118},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41550808. Agents can read the archived copy with the MCP tool read_document.